This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter R. Kerndt, MD; Mark Weber, PhD; Wesley Ford, MPH, MS
Los Angeles County Department of Health Services Los Angeles, Calif

D. Rebecca Prevots, PhD, MPH; J. Stan Lehman, MPH
Centers for Disease Control and Prevention Atlanta, Ga

JAMA. 1995;273(23):1831-1832.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—To estimate the human immunodeficiency virus (HIV) seroconversion rate among injection drug users (IDUs) entering a methadone treatment (maintenance or 21-day detoxification) program in Los Angeles, Calif, we retrospectively reviewed the records of all clients confidentially tested for HIV at one drug treatment center in Los Angeles between March 1989 and January 1994. All IDUs who had a negative HIV test when they first entered drug treatment, who had at least two HIV tests in the first or any subsequent treatment episode during the study period, and who had a history of injection drug use in the 12 months before they entered treatment were included in the analysis. The date of seroconversion was assigned as the midpoint between the last negative and first positive test. Seroconversion rate was calculated as the number of new HIV infections per 1000 person-years of observation.

During the 56-month study period, 3931 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?